FDA Drug Safety Office Would Have $100 Mil. Budget Under Dodd Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
The senator plans to introduce legislation that would establish a new FDA safety office dubbed the Office of Patient Protection. The OPP director would report to the FDA commissioner, and would have the authority to withdraw a drug from the market if it poses a safety risk.
You may also be interested in...
Drug Safety Legislation Unlikely, BIO CEO Greenwood Says
Trade association's new chief sees no "great case for, or inclination on the part of the Senate leadership...to legislate on this topic." Upcoming Health Committee hearings may persuade senators to withdraw proposed legislation on drug safety issues, Greenwood says.
Drug Safety Legislation Unlikely, BIO CEO Greenwood Says
Trade association's new chief sees no "great case for, or inclination on the part of the Senate leadership...to legislate on this topic." Upcoming Health Committee hearings may persuade senators to withdraw proposed legislation on drug safety issues, Greenwood says.
FDA Drug Safety Reform Must Come From Outside Agency – Sen. Grassley
Oversight of the agency's drug safety functions is "going to have to be outside the FDA," Senate Finance Committee Chairman Grassley tells HHS Secretary Leavitt. Grassley still wants drug safety reviewers to have guaranteed independence from the Office of New Drugs, despite plans for a new Drug Safety Oversight Board.